All posts in Cancer

BEVERLY, MA--(Marketwire - May 23, 2011) - Cellceutix Corporation (OTCQB: CTIX) (PINKSHEETS: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical

Agenus Inc. (Nasdaq:AGEN) just announced that it will be presenting new data from a Phase 2 trial of the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent glioma. The

Cellceutix Corporation (OTCQB: CTIX),a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, recently provided additional research data on Kevetrin™, its p53

Cellceutix Corporation (OTCQB: CTIX) is pleased to report that it has submitted for review the "Investigator's Brochure and Clinical Protocol" sections of its Investigational New Drug (IND) application

An article yesterday evening on Reuters detailed results from a recently released ovarian cancer study published on the Journal of Clinical Oncology website. The study by

Kevetrin™ Stands Out in Its Mechanism of Action by Activating Both Transcription-Dependent and Transcription-Independent Pathways to Promote Apoptosis in a Non-Genotoxic Manner and Targets Both Mutated and Wild

– CytRx Plans to Advance Phase 2 Clinical Development for Tumor-Targeting Pro-Drug Candidate as a Treatment for Pancreatic Cancer – – In Earlier Animal Study, Treatment with INNO-206

Cellceutix Corporation (OTCQB: CTIX, "the Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions including drug-resistant cancers, is pleased to

A recent French study at Université Paris Descartes in France indirectly highlights the usefulness of Access Pharmaceuticals' (OTCBB:ACCP) cancer chemotherapy drug ProLindac. The study, led by Dr. J.P.